Scipher Therapeutics

Scipher Medicine is a private precision immunology company that combines network biology, artificial intelligence, and proprietary clinico-transcriptomic data to develop diagnostics, biomarkers, and therapeutic discovery programs. Its lead commercial product is PrismRA, a blood-based molecular test designed to identify rheumatoid arthritis patients unlikely to respond adequately to tumor necrosis factor inhibitor therapies. The company also develops additional response-prediction diagnostics such as PrismUC and PrismPsA and uses its Spectra platform to discover and prioritize new therapeutic targets in autoimmune and inflammatory disease. "Scipher Therapeutics" appears to be an internal or historical therapeutics initiative launched by Scipher Medicine in 2021 rather than the company's primary standalone corporate name. Scipher has partnered with companies including Galapagos, Ionis, Roivant, Maxymune, and Savant Bio to apply its platform across discovery, development, and precision medicine programs.